HEMORRHAGIC PHENOMENA constitute a rare complication of measles infection. Hudson et al1 in their review of the literature, were able to cite only 22 well-documented cases, all of which were secondary to thrombocytopenia. In 1966, Oski and Naiman2 reported the thrombocytopenic effect of live attenuated measles virus vaccine. They demonstrated a significant though generally mild depression of platelets in a large proportion of children receiving this vaccine. However, total platelet count never fell below 64,000, and in no instance were purpuric manifestations noted. We believe the patient reported herein to represent the first recognized case of thrombocytopenic purpura secondary to measles vaccination.
Report of a Case
The patient was a 14-month-old white boy at the onset of thrombocytopenic purpura. He had been delivered by cesarean section at 35 weeks of fetal life, surgery being necessitated by placenta previa. His birth weight was 2,098 gm (4 lb 10 ounces)
Alter HJ, Scanlon RT, Schechter GP. Thrombocytopenic Purpura Following Vaccination With Attenuated Measles Virus. Am J Dis Child. 1968;115(1):111–113. doi:10.1001/archpedi.1968.02100010113022
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: